April 21 (Reuters) – AbbVie has acquired an option
on an early-stage immuno-oncology drug from biotech company
Argenx, giving the U.S. drugmaker access to a
treatment with the potential to block a…
The post AbbVie gets option on early Argenx cancer drug for $40 mln appeared first on NASDAQ.